Investors

BioAdaptives, Inc., (OTCBB: BDPT) was incorporated under the laws of the State of Delaware on April 19, 2013. BioAdaptives is a research, development, marketing, and educational company. Our current focus is on products and strategies that improve health and wellness. These proprietary products include dietary supplements, nutrients, and specialty food items.  Our base of intellectual property and products, which are patent pending nutraceutical solutions are designed to aid in cognition, focus, fatigue reduction, increased testosterone, improved overall emotional and physical wellness, healing, and anti-aging.  The Company's strategy is to develop a position as a leader in supplying science-based quality nutraceutical products to an aging population within developed countries such as the United States, Canada, APAC countries such as China, Japan, Korea, Singapore, Taiwan, Australia and New Zealand, as well as both Western and Eastern Europe. The goal is to create new innovative, health- inspired products to accelerate growth in sales and profitability. Because some of the products, developed for humans, have also proven to be equally as effective on horses and dogs, the Company to has expanded the target market to include livestock and companion pets.

 Since 2014, BioAdaptives®, has been engaged in the research of primitive cells, including stem cells and their derivatives, and natural ingredients which may promote their activities.  Such studies conducted on humans, horses, dogs and other animals, produced encouraging results.  Further research is planned on this and other wellness aspects, such as anti-aging and sports performance.

As of September 2019, BioAdaptives® has launched a majority-owned subsidiary, Livestock Impact, Inc., The purpose is to introduce a full line of natural, effective and cost-friendly wellness supplements to complement  livestock nutrition programs and to educate owners on achieving a simple path to the winners’ circle.  In addition, Livestock Impact, Inc will also offer a wellness and performance line for companion pets.

BioAdaptives® also announced the formation of a new division, TizHemp, to focus on the development, testing, production, and distribution of hemp-based health and wellness products for human and animal application. TizHemp products will utilize the important emerging recognition of various Hemp health benefits and are projected to significantly augment the well-established PrimiCell® line.

 

Dr. Edward E. Jacobs, Jr., a graduate of Princeton University and Harvard Medical school, is a biotechnology consultant with over 25 years’ experience in biopharmaceutical and medical device development, as well as, 35 years of teaching and direct patient care. Dr. Jacobs has participated in drug development process from discovery through animal and human studies, including regulatory support for FDA and international regulatory affairs, strategic planning and investor relations.

Dr. Jacobs has extensive clinical operations experience, having executed more than 15 human trials in the US, Europe, Eastern Europe, and the Republic of South Africa. He has also served as a medical monitor and liaison for clinical investigators involved with international trials with responsibility for regulatory compliance.

After completing surgical training at Harvard and research positions at the National Heart, Lung and Blood Institute, Bethesda, Maryland, and at Saint Thomas’ Hospital Medical School, London, Dr. Jacobs was a member of the Harvard Medical School staff, combining teaching with clinical practice and research. He has also served on the Scientific Advisory Board of the Armenise-Harvard Foundation and the Publications Committee for the New England Journal of Medicine Scientifically, Dr. Jacobs has made original observations in the field of tissue oxygenation therapy and water modification. His current focus is on natural products for animal and human use, anti-ageing strategy, and primitive cell biology.

He is an author of more than 40 scientific publications and is the holder of four patents.

 

 

 

 

 

 

 

 

Robert Ellis brings more than forty years of business management experience to the Company.  He has worked extensively in senior positions across a variety of industry disciplines, including aerospace, electronics, communications, and international marketing.  Mr. Ellis has been an executive officer in private and public companies, both major entities, start-ups, and emerging entities.  He has an Accounting Degree from the University of Illinois, and is a CPA.

 

 

Ron Lambrecht is a successful businessman from Western Montana.  He is a CPA and has operated a financial services business for more than 30 years.  As a finance participant, he has been involved in a number of technology acquisitions and joint ventures.  He graduated from the University of Montana in 1971 with a degree in Accountancy.  Mr. Lambrecht is recognized as an expert in the fields of surface mining in addition to oil and gas exploration

Press Releases

SEC Edgar and OTC Filings